Date Title Description PDF
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download

Pages

Date Title Description PDF
02 Apr 2024 On business and financial situation ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia Download
29 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 March and 27 March 2024 Download
22 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 March and 21 March 2024 Download
15 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 8 March and 14 March 2024 Download
12 Mar 2024 On business and financial situation ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies Download

Pages

Date Title Description PDF
08 Oct 2018 Share capital increases and reductions Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase Download
05 Oct 2018 Buy-back programmes, stabilisation and treasury stock Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. Download
04 Oct 2018 Share capital increases and reductions Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights Download
04 Oct 2018 Liquidity contracts and specialists The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. Download
04 Oct 2018 Share capital increases and reductions Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights Download

Pages